Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: direct and indirect comparison meta-analysis
MS Kwak, JM Cha, JY Yoon, JW Jeon, HP Shin… - Medicine, 2017 - journals.lww.com
Background: The clinical significance of KRAS codon 13 mutation in patients with colorectal
cancer (CRC) remains controversial. A systematic review and meta-analysis is necessary for …
cancer (CRC) remains controversial. A systematic review and meta-analysis is necessary for …
A phase II efficacy and safety, open-label, multicenter study of imprime PGG injection in combination with cetuximab in patients with stage IV KRAS-mutant colorectal …
NH Segal, P Gada, N Senzer, MA Gargano… - Clinical colorectal …, 2016 - Elsevier
Abstract Background Imprime PGG (β (1, 6)-[poly-(1, 3)-D-glucopyranosyl]-poly-β (1, 3)-D-
glucopyranose) is an innate immune cell modulator that primes neutrophils and monocytes …
glucopyranose) is an innate immune cell modulator that primes neutrophils and monocytes …
Variation in KRAS/NRAS/BRAF-Mutation Status by Age, Sex, and Race/Ethnicity Among a Large Cohort of Patients with Metastatic Colorectal Cancer (mCRC)
BD Booker, SC Markt, FR Schumacher, J Rose… - Journal of …, 2024 - Springer
Background Racial/ethnic disparities in metastatic colorectal cancer (mCRC) survival are
well documented as is the impact that tumor mutation of KRAS and BRAF has on prognosis …
well documented as is the impact that tumor mutation of KRAS and BRAF has on prognosis …
Personalized treatment for patients with colorectal cancer: role of biomarkers
MJ Duffy - Biomarkers in medicine, 2015 - Taylor & Francis
The systemic treatment of patients with colorectal cancer (CRC) has traditionally been based
on clinical and tumor histological criteria. Recently however, several prognostic and …
on clinical and tumor histological criteria. Recently however, several prognostic and …
Metabolic Response to Small Molecule Therapy in Colorectal Cancer Tracked with Raman Spectroscopy and Metabolomics
Despite numerous screening tools for colorectal cancer (CRC), 25% of patients are
diagnosed with advanced disease. Novel diagnostic technologies that are early, accurate …
diagnosed with advanced disease. Novel diagnostic technologies that are early, accurate …
RAS mutations as predictive biomarkers in clinical management of metastatic colorectal cancer
P Waring, J Tie, D Maru, CS Karapetis - Clinical colorectal cancer, 2016 - Elsevier
The use of anti–epidermal growth factor receptor (EGFR) monoclonal antibody therapies in
patients with metastatic colorectal cancer is guided by the presence of activating point …
patients with metastatic colorectal cancer is guided by the presence of activating point …
Interface-guided phenotyping of coding variants in the transcription factor RUNX1
Single-gene missense mutations remain challenging to interpret. Here, we deploy scalable
functional screening by sequencing (SEUSS), a Perturb-seq method, to generate mutations …
functional screening by sequencing (SEUSS), a Perturb-seq method, to generate mutations …
The prevalent KRAS exon 2 c. 35 G> A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab …
Bevacizumab-containing chemotherapy differently predict increased efficacy in KRAS exon
2 mutant and wild-type metastatic colorectal cancer (MCRC) patients. Mutant compared to …
2 mutant and wild-type metastatic colorectal cancer (MCRC) patients. Mutant compared to …
[HTML][HTML] ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
AL Geißler, M Geißler, D Kottmann, L Lutz, CD Fichter… - Oncotarget, 2017 - ncbi.nlm.nih.gov
EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic
colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted …
colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted …
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic …
N Calonge, NL Fisher, AO Berg… - Genetics in …, 2013 - ohsu.elsevierpure.com
Abstract Summary of recommendations: The Evaluation of Genomic Applications in Practice
and Prevention (EGAPP) Working Group (EWG) found that, for patients with metastatic …
and Prevention (EGAPP) Working Group (EWG) found that, for patients with metastatic …